Anbio Biotechnology

Das jüngste Quartal, das uns für Anbio Biotechnology vorliegt

Aus dem eigenen 6-K des Unternehmens.

Was Anbio Biotechnology macht

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of IVD products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and six key platforms for biomarker detection. These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a strong global presence across the EU, APAC, and the Americas, the Company’s Conformité Européenne (CE)-marked products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.

Die Selbstbeschreibung des Unternehmens, wie sie am Fuß der Veröffentlichung steht.